We are live on ! Find out more
MYGN icon

Myriad Genetics

188 hedge funds and large institutions have $1.88B invested in Myriad Genetics in 2023 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 65 increasing their positions, 64 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

3,704% more call options, than puts

Call options by funds: $16.5M | Put options by funds: $433K

2% more repeat investments, than reductions

Existing positions increased: 65 | Existing positions reduced: 64

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

2% less capital invested

Capital invested by funds: $1.91B → $1.88B (-$30.8M)

9% less first-time investments, than exits

New positions opened: 21 | Existing positions closed: 23

1% less funds holding

Funds holding: 190188 (-2)

1.75% less ownership

Funds ownership: 101.27%99.52% (-1.7%)

Holders
188
Holders Change
-2
Holders Change %
-1.05%
% of All Funds
2.95%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
21
Increased
65
Reduced
64
Closed
23
Calls
$16.5M
Puts
$433K
Net Calls
+$16M
Net Calls Change
-$1.01M

MYGN Hedge Fund Activity: Q2 2023 in Review

188 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Myriad Genetics (MYGN) for Q2 2023, worth a combined $1.88B — down 1.6% from $1.91B a quarter earlier.

Sellers outnumbered buyers: 23 funds closed out of MYGN and 21 opened new positions — a net loss of 2 holders — while 64 trimmed existing stakes and 65 added.

The largest buyer was ExodusPoint Capital Management, opening a new position worth an estimated $7.89M. The largest seller was Wellington Management Group, cutting an estimated $21.5M.

  • 188 institutional investors held Myriad Genetics (MYGN) as of Q2 2023, down from 190 in Q1 2023.
  • Funds reported $1.88B of Myriad Genetics stock for Q2 2023, down 1.6% quarter-over-quarter.
  • 21 funds opened new Myriad Genetics positions in Q2 2023 and 23 closed out, a net change of -2 holders.
  • The largest Myriad Genetics buyer in Q2 2023 was ExodusPoint Capital Management, an estimated $7.89M added.
  • The largest Myriad Genetics seller in Q2 2023 was Wellington Management Group, an estimated $21.5M sold.

Based on aggregated 13F filings for Q2 2023.